.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Argus Health
Colorcon
Medtronic
Accenture
McKesson
QuintilesIMS
Johnson and Johnson
Mallinckrodt
Chubb

Generated: November 20, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Details for Patent: ► Subscribe

Title: Compositions for treatment of glaucoma
Abstract:Compositions for controlling glaucoma and ocular hypertension are disclosed.
Inventor(s): Ali; Yusuf (Forth Worth, TX), Jani; Rajni (Forth Worth, TX), McCarty; George R. (Forth Worth, TX)
Assignee: Alcon Laboratories, Inc. (Fort Worth, TX)
Filing Date:Nov 04, 1994
Application Number:08/334,512
Claims:1. A topical ophthalmic composition for controlling glaucoma and/or ocular hypertension comprising 0.1 to 1.0 wt./vol. % betaxolol, 0.25 to 10.0 wt./vol. % pilocarpine, 0.05 to 10.0 wt./vol. % poly(styrene-divinyl benzene) sulfonic acid, and 0.01 to 5.0 wt./vol. % polyanionic polymer selected from the group consisting of Carbomer 934P and Carbomer 974P.

2. The composition of claim 1 wherein the polyanionic polymer is Carbomer 934P.

3. The composition of claim 2 wherein the betaxolol concentration is 0.25%, the pilocarpine concentration is 1.75%, the resin concentration is 0.25%, and the Carbomer 934P concentration is 0.40%.

4. The composition of claim 1 wherein the polyanionic polymer is Carbomer 974P.

5. The composition of claim 4 wherein the betaxolol concentration is 0.25%, the pilocarpine concentration is 1.75%, the resin concentration is 0.25%, and the Carbomer 974P concentration is 0.40%.

6. A method for controlling intraocular pressure by topically applying to the eye a composition which comprises 0.1 to 1.0 wt./vol. % betatolol, 0.25 to 10.0 wt./vol. % pilocarpine, 0.05 to 10.0 wt./vol. % poly(styrene-divinyl benzene) sulfonic acid, and 0.01 to 5.0 wt./vol. % polyanionic polymer selected from the group consisting of Carbomer 934P and Carbomer 974P.

7. The method of claim 6 wherein the polyanionic polymer is Carbomer 934P.

8. The method of claim 7 wherein the betaxolol concentration is 0.25%, the pilocarpine concentration is 1.75%, the resin concentration is 0.25%, and the Carbomer 934P concentration is 0.40%.

9. The method of claim 6 wherein the polyanionic polymer is Carbomer 974P.

10. The method of claim 9 wherein the betaxolol concentration is 0.25%, the pilocarpine concentration is 1.75%, the resin concentration is 0.25%, and the Carbomer 974P concentration is 0.40%.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Merck
Chinese Patent Office
Harvard Business School
Chubb
US Army
Accenture
Teva
Cipla
AstraZeneca
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot